skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Vantictumab (Code C96799)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Vantictumab

Definition: A monoclonal antibody directed against the Wnt signaling pathway with potential antineoplastic activity. Upon administration, vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This may result in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. The Wnt signaling pathway is dysregulated in many cancer cell types and appears to play a major role in CSC regulation and activity; CSC are tumor initiating cells that are able to self-renew and are responsible for tumor growth and resistance.

Display Name: Vantictumab

Label: Vantictumab

NCI Thesaurus Code: C96799 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL429406  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
PDQ Closed Trial Search ID 700131
PDQ Open Trial Search ID 700131 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C96799
Contributing_Source CTRP
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom